Screener / SEC EDGAR /CIK 0001061983 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Cytokinetics Inc CYTK

Compare with peers Embed
FY2025 at a glance

Sales up 376.6%, free cash flow down to -$534.8M

XBRL, from each 10-K
RevenueStatements
$88.0M from $18.5M in FY2024
FY2016FY2025
Net incomeStatements
-$785.0M from -$589.5M in FY2024
FY2016FY2025
Free cash flowStatements
-$534.8M from -$399.8M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-6.54 from $-5.26 in FY2024
FY2016FY2025
Operating marginStatements
-695.4% from -2902.7% in FY2024
FY2016FY2025
Total debtStatements
$287.6M from $619.5M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (36)
EPS (ttm)
-6.02
Sales (ttm)
113.3M
Net income (ttm)
-777.9M
Sales growth
+377%
EPS growth
-
Sales Q/Q
n/m
Free cash flow
-588.6M
Gross margin
-
Oper. margin
-625.2%
Net margin
-686.6%
FCF margin
-519.5%
ROE
n/m
R&D / sales
472.5%
Dividend
-
Debt/Eq
n/m
Curr. ratio
3.36
Cash
203.4M
Op. cash flow (ttm)
-572.0M
EBITDA
-602.1M
EBITDA margin
-683.9%
Net debt
215.3M
Quick ratio
3.36
Interest cover
-13.43
FCF after stock pay
-647.1M
Oper. margin low 5y
-6589.7%
Stock pay / sales
127.5%
Shares out.
139.3M
Shares Y/Y
+7.3%
Book / share
-2.31
Cash / share
1.46
Sales / share
0.81
Asset turnover
0.06
Days sales out.
74
Sales 3Y CAGR
-2.4%
Sales 5Y CAGR
+9.5%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 88.0M -2.1% a year Net income -785.0M
FY2016 revenue 106.4M · Revenues, 0001564590-18-004398 FY2016 net income 16.5M · NetIncomeLoss, 0001564590-18-004398 106.4M FY2016 FY2017 revenue 13.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-006580 FY2017 net income -127.8M · NetIncomeLoss, 0001564590-19-006580 13.4M FY2017 FY2018 revenue 31.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-009467 FY2018 net income -106.3M · NetIncomeLoss, 0001564590-21-009467 31.5M FY2018 FY2019 revenue 26.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-007218 FY2019 net income -121.7M · NetIncomeLoss, 0001564590-22-007218 26.9M FY2019 FY2020 revenue 55.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-005515 FY2020 net income -127.3M · NetIncomeLoss, 0000950170-23-005515 55.8M FY2020 FY2021 revenue 70.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-022256 FY2021 net income -215.3M · NetIncomeLoss, 0000950170-24-022256 70.4M FY2021 FY2022 revenue 94.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-029206 FY2022 net income -389.0M · NetIncomeLoss, 0000950170-25-029206 94.6M FY2022 FY2023 revenue 7.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-076495 FY2023 net income -526.2M · NetIncomeLoss, 0001193125-26-076495 7.5M FY2023 FY2024 revenue 18.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-076495 FY2024 net income -589.5M · NetIncomeLoss, 0001193125-26-076495 18.5M FY2024 FY2025 revenue 88.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-076495 FY2025 net income -785.0M · NetIncomeLoss, 0001193125-26-076495 88.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $917.0M
  • − All liabilities $2.1B
  • = Net current asset value -$1.2B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $659.6M
  • = Tangible book value -$659.6M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

CYTK against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+377%2nd of 155 · median +10.5%
Net margin
-4.1%15.3%
-686.6%151st of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-519.5%142nd of 145 · median 10.0%
CYTK and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
CYTK Cytokinetics Inc$113.3M +377%--686.6%--519.5%-
GRAL GRAIL, Inc.$166.6M +17.2%--243.8%-16.6%-187.3%-
BEAM Beam Therapeutics Inc.$146.6M +120%--73.9%-11.4%-271.6%0.11
AGIO Agios Pharmaceuticals, Inc.$140.8M +48.0%93.8%-264.8%-38.1%-238.5%-
KYMR Kymera Therapeutics, Inc.$102.2M -16.7%--341.8%-21.6%-282.6%-
RXRX Recursion Pharmaceuticals, Inc.$68.2M +26.9%5.0%-697.1%-52.5%-458.0%0.01
All 162 companies in the group

Where the $88.0M of revenue came from

by product, year to Dec 31, 2025

  • License and Milestone Revenues $79.4M · 90%
  • Collaboration Revenues $8.7M · 10%

From the segment tables in the 10-K XBRL.

Profitability

  • Net margin below the peer median
    -686.6% vs 6.8%
  • A profit in 1 of 10 years
Net margin, FY2016 to FY2025: 15.5% to -891.6%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -13.4× interest expense
  • Equity below zero
    Debt $418.7M, equity −$321.2M
  • Current assets cover current liabilities
    Current ratio 3.36
  • More cash than debt
    Net cash $544.4M
Debt / equity at each year end, FY2016 to FY2025: 0.32 to 0.19

Cash and shareholders

  • Free cash flow positive in 1 of 10 years
    −$534.8M last year
  • Share count up over 5 years
    +86.1%
Free cash flow, FY2016 to FY2025: 35.4M to -534.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$999.0M of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Deferred revenue, current part

Paid in advance $1.7M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +2.5% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

CYTK's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue88.0M
FY2016: 106.4MFY2017: 13.4MFY2018: 31.5MFY2019: 26.9MFY2020: 55.8MFY2021: 70.4MFY2022: 94.6MFY2023: 7.5MFY2024: 18.5MFY2025: 88.0M FY2017FY2019FY2021FY2023FY2025
Net income-785.0M
FY2016: 16.5MFY2017: -127.8MFY2018: -106.3MFY2019: -121.7MFY2020: -127.3MFY2021: -215.3MFY2022: -389.0MFY2023: -526.2MFY2024: -589.5MFY2025: -785.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow-534.8M
FY2016: 35.4MFY2017: -104.6MFY2018: -102.1MFY2019: -93.5MFY2020: -2.1MFY2021: -191.4MFY2022: -310.9MFY2023: -415.7MFY2024: -399.8MFY2025: -534.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-647.1M
FY2016: 28.2MFY2017: -113.7MFY2018: -111.9MFY2019: -104.3MFY2020: -19.7MFY2021: -218.2MFY2022: -358.7MFY2023: -487.8MFY2024: -497.6MFY2025: -647.1M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-6.54
FY2016: 0.39FY2017: -2.59FY2018: -1.95FY2019: -2.11FY2020: -1.97FY2021: -2.80FY2022: -4.33FY2023: -5.45FY2024: -5.26FY2025: -6.54 FY2017FY2019FY2021FY2023FY2025
Diluted shares120K
FY2016: 42.6MFY2017: 49.4MFY2018: -FY2019: -FY2020: 65KFY2021: 77KFY2022: 90KFY2023: 97KFY2024: 112KFY2025: 120K FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
License and Milestone Revenues 79.4M90.1% +429%
Collaboration Revenues 8.7M9.9% +150%

10-K 0001193125-26-076495, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue106.4M13.4M31.5M26.9M55.8M70.4M94.6M7.5M18.5M88.0M
R&D59.9M90.3M89.1M86.1M97.0M159.9M240.8M330.1M339.4M416.0M
SG&A27.8M36.5M31.3M39.6M52.8M96.8M178.0M173.6M215.3M284.3M
Operating income18.7M-113.4M-88.9M-98.9M-93.9M-186.3M-324.2M-496.2M-536.2M-612.3M
Interest expense2.7M3.0M3.8M6.6M16.0M16.4M19.4M28.3M37.7M45.6M
Pretax income16.5M-127.8M-106.3M-------
Income tax0000000000
Net income16.5M-127.8M-106.3M-121.7M-127.3M-215.3M-389.0M-526.2M-589.5M-785.0M
EPS (diluted)0.39-2.59-1.95-2.11-1.97-2.80-4.33-5.45-5.26-6.54
Diluted shares42.6M49.4M--65K77K90K97K112K120K
Depreciation & amortization741K1.9M1.2M1.3M1.8M2.3M5.8M11.9M9.5M10.1M
EBITDA19.4M-111.5M-87.7M-97.6M-92.1M-184.0M-318.4M-484.3M-526.7M-602.1M
Operating margin17.6%-848.3%-282.3%-368.0%-168.3%-264.5%-342.8%-6589.7%-2902.7%-695.4%
Net margin15.5%-955.9%-337.4%-452.9%-228.0%-305.7%-411.2%-6988.6%-3191.1%-891.6%
Revenue growth+271%-87.4%+136%-14.7%+108%+26.2%+34.3%-92.0%+145%+377%
EPS growth-to a loss--------

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow37.0M-101.8M-101.2M-90.9M8.9M-142.5M-299.5M-414.3M-395.9M-510.0M
Capital spending1.6M2.9M889K2.6M11.1M48.9M11.3M1.4M3.9M24.8M
Free cash flow35.4M-104.6M-102.1M-93.5M-2.1M-191.4M-310.9M-415.7M-399.8M-534.8M
Stock-based pay (added back)7.1M9.0M9.8M10.8M17.6M26.8M47.9M72.1M97.8M112.3M
Free cash flow after stock pay28.2M-113.7M-111.9M-104.3M-19.7M-218.2M-358.7M-487.8M-497.6M-647.1M
Debt raised15.0M1.3M9.9M1.7M00----
Debt repaid----0047.7M08.7M10.8M
Investing cash flow-52.1M-65.8M5.1M-74.7M-196.5M-147.8M-262.1M239.3M-553.1M16.7M
Financing cash flow16.9M225.9M13.1M159.8M234.1M320.0M516.2M221.3M930.6M524.5M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)7.1M9.0M9.8M10.8M17.6M26.8M47.9M72.1M97.8M112.3M
Stock-based pay / revenue6.7%67.5%31.0%40.0%31.6%38.1%50.6%957.0%529.6%127.5%
Operating lease cash paid---5.0M6.7M-----
Finance lease principal paid----00944K858K939K204K
Right-of-use assets--9.6M-2.9M73.1M82.7M79.0M75.2M76.0M
Operating lease liabilities--10.7M6.8M3.2M127.1M139.7M138.3M131.6M127.1M
Finance lease liabilities-----1.3M2.0M1.1M204K-

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CYTK/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.